A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

In the field of invasive treatment of coronary artery disease (CAD), the past two decades have been characterised by the ...

Journalists covering COVID-19 faced an extraordinarily challenging task of keeping the public informed in a hyper-politicized climate filled with misinformation and reliance on unsubstantiated ...

Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously ...

Tocilizumab significantly reduced 28-day mortality and length of ICU stay in patients with severe COVID-19 pneumonia and low S-spike nAb titers.

In a new study, researchers investigated the impact of trial study design and other parameters on the estimates of COVID-19 vaccine efficacy.

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

AstraZeneca said its latest figure on the vaccine’s efficacy was based on an analysis of 190 cases of symptomatic Covid-19 in the trial, 49 more cases than the company had analyzed earlier.

The global AI in drug discovery market size was US$ 910.7 million in 2021. The global AI in drug discovery market size is forecast to reach US$ 9,072.2 million by 2030, growing at a compound annual ...

Single doses of 150 milligrams (mg), 300 mg, and 450 mg provided 58%, 61%, and 76% protection from symptomatic flu, ...